NCT02280252View on ClinicalTrials.gov

Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response

PHASE2CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

December 20, 2018

Study Completion Date

December 20, 2018

Conditions
Breast Cancer
Interventions
DRUG

Paclitaxel

Paclitaxel (including Abraxane), 30 mg/m2 twice per week. Paclitaxel will be given IV over 1 hour, Abraxane® will be administered over 30 min, and administered on a Monday/Thursday or Tuesday/Friday schedule.

RADIATION

Radiation therapy

Patients will receive a total dose of 45 Gy to the breast, axilla and supraclavicular area at 1.8 Gy/fraction, +14 Gy to the original palpable tumor at 2 Gy/fraction (total 32 fractions)

Trial Locations (1)

10016

NYU Langone Medical Center, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER

NCT02280252 - Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response | Biotech Hunter | Biotech Hunter